Sept 22, Resitu Medical wins Healthy Longevity Catalyst Award and receives 50 kUSD
Resitu Medical is one of 154 winners selected among 1500 applicants from 50 countries to win the Healthy Longevity Catalyst Award from the US National Academy of Medicine, and receives 50 kUSD. Resitu Medical was selected by EIT Health as 1 of 21 winners from more than 400 applicants in the European Union.
We would like thank the National Academy of Medicine and EIT Health for selecting Resitu Medical as a winner of the Healthy Longevity Catalyst Award. We aim to contribute to health and longevity by enabling correct and early diagnosis and faster treatment of breast cancer. The true winners will be the women with breast lesions and tumours who will get access to the minimally invasive Resitu technology offering them a fast and safe diagnosis giving better treatment outcomes. Our cost effective technology will also bring substantial health economic gains for the benefit of the society.
August 15, Resitu Medical welcomes Henrik
We are happy to announce that we have recruited Henrik Thunqvist as a new employee. Henrik has collaborated with Resitu Medical when writing his master thesis, to finish his studies of Engineering Physics in Uppsala.
Henrik has been focusing on the specific heat distribution that electrosurgery can cause, a complex process which depends on multiple factors. He has also done in-depth studies of electrosurgery and diathermy and how these methods are used today, subjects important for the design of the Resitu instrument. Henrik brings important knowledge to Resitu Medical and we are very happy to welcome him to the team!
The medical technology company Resitu Medical AB, working with an innovative solution for tumor biopsies, announced today that Almi Invest, Stockholm Business Angels (STOAF) and private investors have invested €750 000 in the company. The investment will be used to initiate a development project aiming for CE marking in 2023. An additional SEK 20 million will be raised through equity.
Almi Invest and STOAF III Scitech invest 2.5 MSEK each in Resitu Medical, for their development of a new instrument for early treatment of breast cancer. Other private investors are also participating in the issue totalling SEK 7.5 million. The money will be used for product development of a version of the instrument ready for CE marking.
Resitu Medical has been accepted in taking part in this year's matchmaking event for investors and companies wanting to attract financing.
ReSitu Medical has received a 50,000 Euro grant from the EIT Health Headstart programme.
ReSitu Medical is one of the Scandinavian startups selected for the 2020 annual EIT Health Headstart programme.